Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation
- PMID: 21861534
- PMCID: PMC3189276
- DOI: 10.1021/pr2005583
Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation
Abstract
The lack of experimental characterization of the structures and ligand-binding motifs of therapeutic G-protein coupled receptors (GPCRs) hampers rational drug discovery. The human cannabinoid receptor 2 (hCB2R) is a class-A GPCR and promising therapeutic target for small-molecule cannabinergic agonists as medicines. Prior mutational and modeling data constitute provisional evidence that AM-841, a high-affinity classical cannabinoid, interacts with cysteine C6.47(257) in hCB2R transmembrane helix 6 (TMH6) to afford improved hCB2R selectivity and unprecedented agonist potency. We now apply bottom-up mass spectrometry (MS)-based proteomics to define directly the hCB2R-AM-841 interaction at the amino-acid level. Recombinant hCB2R, overexpressed as an N-terminal FLAG-tagged/C-terminal 6His-tagged protein (FLAG-hCB2R-6His) with a baculovirus system, was solubilized and purified by immunochromatography as functional receptor. A multiplex multiple reaction monitoring (MRM)-MS method was developed that allowed us to observe unambiguously all seven discrete TMH peptides in the tryptic digest of purified FLAG-hCB2R-6His and demonstrate that AM-841 modifies hCB2R TMH6 exclusively. High-resolution mass spectra of the TMH6 tryptic peptide obtained by Q-TOF MS/MS analysis demonstrated that AM-841 covalently and selectively modifies hCB2R at TMH6 cysteine C6.47(257). These data demonstrate how integration of MS-based proteomics into a ligand-assisted protein structure (LAPS) experimental paradigm can offer guidance to structure-enabled GPCR agonist design.
Figures






Similar articles
-
Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.ACS Chem Neurosci. 2017 Jun 21;8(6):1338-1347. doi: 10.1021/acschemneuro.7b00003. Epub 2017 Mar 1. ACS Chem Neurosci. 2017. PMID: 28220706
-
Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.J Proteome Res. 2017 Jul 7;16(7):2419-2428. doi: 10.1021/acs.jproteome.7b00023. Epub 2017 Jun 19. J Proteome Res. 2017. PMID: 28374590 Free PMC article.
-
Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor.J Proteome Res. 2007 Jun;6(6):2068-79. doi: 10.1021/pr060671h. Epub 2007 May 2. J Proteome Res. 2007. PMID: 17472360
-
Elucidating structural and molecular mechanisms of β-arrestin-biased agonism at GPCRs via MS-based proteomics.Cell Signal. 2018 Jan;41:56-64. doi: 10.1016/j.cellsig.2017.09.013. Epub 2017 Sep 20. Cell Signal. 2018. PMID: 28939107 Review.
-
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.Curr Med Chem. 2008;15(14):1428-43. doi: 10.2174/092986708784567716. Curr Med Chem. 2008. PMID: 18537620 Review.
Cited by
-
3'-functionalized adamantyl cannabinoid receptor probes.J Med Chem. 2015 Apr 9;58(7):3104-16. doi: 10.1021/jm501960u. Epub 2015 Mar 20. J Med Chem. 2015. PMID: 25760146 Free PMC article.
-
Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor.Sci Rep. 2018 Feb 13;8(1):2935. doi: 10.1038/s41598-018-19749-5. Sci Rep. 2018. PMID: 29440756 Free PMC article.
-
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.Br J Pharmacol. 2015 May;172(9):2406-18. doi: 10.1111/bph.13069. Epub 2015 Feb 27. Br J Pharmacol. 2015. PMID: 25572435 Free PMC article.
-
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.Neurogastroenterol Motil. 2015 Dec;27(12):1721-35. doi: 10.1111/nmo.12668. Epub 2015 Sep 20. Neurogastroenterol Motil. 2015. PMID: 26387676 Free PMC article.
-
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).J Med Chem. 2016 Jan 14;59(1):44-60. doi: 10.1021/acs.jmedchem.5b01303. Epub 2015 Nov 28. J Med Chem. 2016. PMID: 26529344 Free PMC article.
References
-
- Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro. Endocrinol. Lett. 2009;30:153–179. - PubMed
-
- Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic application. Pharmacol. Res. 2009;60:77–84. - PubMed
-
- Demuth DG, Molleman A. Cannabinoid signaling. Life Sci. 2006;78:549–563. - PubMed
-
- Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin. Emerg. Drugs. 2009;14:43–65. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources